1. Salinger CL, Gaynes BI, Rajpal RK. Innovations in topical ocular corticoseroid therapy for the management of postoperative ocular inflammation and pain. Am J Manag Care. 2019;25(12 suppl):S215–26.
2. Grob SR, Gonzalez-Gonzalez LA, Daly MK. Management of mydriasis and pain in cataract and intraocular lens surgery: review of current medications and future directions. Clin Ophthalmol. 2014;8:1281–9.
3. Marlowe ZT, Davio SR. Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%). Clin Ophthalmol. 2014;8:23–9.
4. Apt L, Henrick A, Silverman L. Patient compliance with use of topical opthalmic corticosteroid suspensions. Am J Ophthalmol. 1979;87:210–4.
5. Bausch & Lomb Incorporated. Lotemax SM (loteprednol etabonate) ophthalmic gel 0.38% [package insert]. Bridgewater: Bausch & Lomb Incorporated; 2020.